Idorsia declares the appointment of Dr. Amer Joseph as Executive Vice President, Chief Medical Officer (CMO), and Head of Global Clinical Development, starting May 1, 2026. He replaces Dr. Alberto Gimona, who is stepping down.
Amer is a skilled leader in clinical development with a proven history of managing regulatory submissions, implementing mid and late stage global clinical development initiatives, creating high-performing teams, and promoting operational excellence with precision, discipline, and swiftness.
His leadership – grounded in scientific rigor, curiosity, and a profound sense of ownership – embodies Idorsia’s culture of innovation, flexibility, and intentional execution.
Jean-Paul Clozel, MD, Chairman and interim CEO of Idorsia says, “I’m delighted to welcome Amer to Idorsia. His breadth of clinical development experience, passion for advancing science, collaborative leadership style, and energetic, open approach make him an outstanding addition to our organization. Amer brings exactly the vision, discipline, and patient-focused mindset we need as we sharpen our scientific priorities and accelerate progress on our most promising assets. I’m confident he will strengthen our ability to deliver meaningful medicines to patients.”
Amer Joseph, MD says, “I am truly excited to be joining Idorsia. The company has a remarkable scientific legacy, a strong culture of innovation, and a broad pipeline with real potential to make a difference in the lives of millions of patients. I look forward to working with the leadership team, and the talented teams across the company to advance our medicines with scientific rigor and a deep sense of purpose.”
Also Read: Hungary and Russia Seal 12-Point Pact to Boost Relations
Amer joins Idorsia from Chiesi Group, where he most recently served as Vice President, Head of Global Clinical Development, leading a global organization spanning clinical development, clinical operations, biometrics, real-world evidence, and digital health.
He delivered late‑stage development programs in respiratory, neonatology, cardiovascular and rare diseases, launched three products in 2023, and drove multiple FDA and EMA approvals.
Also Read: Q.ANT Appoints Michael Krueger as Vice President of Commercials
Amer previously spent more than nine years at Bayer, where he held international leadership positions in cardiology and nephrology. He was instrumental in creating the blockbuster cardio-renal franchise finerenone, overseeing Phase 2 and Phase 3 programs with 13,000 patients in 48 countries and guiding interactions with global health authorities. He additionally obtained experience with rare diseases at GSK, offering clinical leadership for initiatives in transthyretin amyloidosis.
Also Read: Greece to Ban Social Media for Under-15s from 2027, Says PM
Amer started his professional journey as a clinician in the UK, serving in prominent London hospitals such as the London Chest Hospital, St Bartholomew’s, and the Royal London Hospital. He possesses extensive knowledge of the heart-kidney-metabolic axis, robust interaction with key opinion leaders both globally and in the US, and significant experience working alongside commercial and medical affairs to develop unique clinical strategies.